CORRECTION article

Front. Pharmacol., 13 May 2025

Sec. Inflammation Pharmacology

Volume 16 - 2025 | https://doi.org/10.3389/fphar.2025.1611115

Corrigendum: C16 peptide promotes vascular growth and reduces inflammation in a neuromyelitis optica model

This article is a correction to:

  1. C16 Peptide Promotes Vascular Growth and Reduces Inflammation in a Neuromyelitis Optica Model

    1. Read original article
Haohao Chen&#x;Haohao Chen1†Xiaoxiao Fu&#x;Xiaoxiao Fu2†Jinzhan JiangJinzhan Jiang1Shu Han Shu Han2*
  • 1Medical Molecular Biology Laboratory, School of Medicine, Jinhua Polytechnic, Jinhua, China
  • 2Institute of Anatomy and Cell Biology, Medical College, Zhejiang University, Hangzhou, China

A Corrigendum on
C16 peptide promotes vascular growth and reduces inflammation in a neuromyelitis optica model

by Chen H, Fu X, Jiang J and Han S (2019). Front. Pharmacol. 10:1373. doi: 10.3389/fphar.2019.01373

In the published article, there was an error in Supplementary Figure S1 as published. The magnification of subfigure B and G of Supplementary Figure S1 is different from others. The corrected Supplementary Figure S1 and its caption “Immunofluorescence images of Tie2 expression in transverse sections through the anterior horn of the lumbar SC in (A- I) normal and NMO rats treated with (C, G) C16, (D, H) Tie2 KI + C16 and (E, I) LY294002 + C16 at 3 and 8 weeks P.I. Scale bar = 100 μm. (J) Plot of Tie2+ blood vessels. a, P < 0.05 versus normal group; b, P < 0.05 versus the vehicle-treated group; c, P < 0.05 versus the C16-treated group; d, P < 0.05 versus Tie2 KI + C16 group. Tie2 loss in the ON of vehicle-treated NMO rats is indicated by the arrow in B, F.” has been updated in the original article.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: C16 peptide, receptor tyrosine kinase Tie2, PI3K/Akt pathways, αvβ3 integrin, neuromyelitis optica (NMO)

Citation: Chen H, Fu X, Jiang J and Han S (2025) Corrigendum: C16 peptide promotes vascular growth and reduces inflammation in a neuromyelitis optica model. Front. Pharmacol. 16:1611115. doi: 10.3389/fphar.2025.1611115

Received: 13 April 2025; Accepted: 30 April 2025;
Published: 13 May 2025.

Edited and reviewed by:

Stefania Tacconelli, University of Studies G. d’Annunzio Chieti and Pescara, Italy

Copyright © 2025 Chen, Fu, Jiang and Han. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Shu Han, aGFuMDBzaHVAemp1LmVkdS5jbg==

†These authors have contributed equally to this work

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.